Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 2Withdrawn 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Endocrine 2CNS 2Thoracic 1Sarcoma 1Other hematologic neoplasm 1NET 1Lymphoid 1Dermatologic 1Breast 1

Conditions

Neuroendocrine Tumors 3Small Cell Lung Carcinoma 2Meningioma 2Medulloblastoma 2Lung Neoplasms 2Breast Neoplasms 2Vipoma 1Somatostatinoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pituitary Neoplasms 1Pinealoma 1Oligodendroglioma 1Neuroectodermal Tumors, Primitive 1Neuroblastoma 1Neoplasms 1Melanoma 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Large-Cell, Immunoblastic 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma 1Leukemia, Lymphocytic, Chronic, B-Cell 1Insulinoma 1Hodgkin Disease 1Growth Hormone-Secreting Pituitary Adenoma 1Glucagonoma 1Gliosarcoma 1Glioma, Subependymal 1

Interventions

Hydroxyurea 4aldesleukin 3Magnetic Resonance Spectroscopy 3Imatinib Mesylate 3Everolimus 3Temozolomide 2Surveys and Questionnaires 2Surgical Procedures, Operative 2Radiotherapy, Intensity-Modulated 2Radiotherapy, Conformal 2Psychiatric Rehabilitation 2Proton Therapy 2Paclitaxel 2Laser Speckle Contrast Imaging 2Filgrastim 2Donepezil 2Cyclophosphamide 2Carmustine 2Bortezomib 2Bevacizumab 2Aminolevulinic Acid 290Y-octreotide, DOTA-Tyr(3)- 2vistusertib 1vatalanib 1trametinib 1tozuleristide 1temsirolimus 1sonidegib 1sargramostim 1ribociclib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Meningioma × 90Y-octreotide, DOTA-Tyr(3)- × Clear all
NCT03273712 2023-02-09

Dosimetry-Guided, Peptide Receptor Radiotherapy (PRRT) With 90Y-DOTA- tyr3-Octreotide (90Y-DOTATOC)

University of Iowa

Phase 2 Completed
39 enrolled 9 charts
CNSEndocrineNET

Medulloblastoma, Meningioma, Neuroblastoma, Neuroendocrine Tumors

NCT00006368 2013-05-01

Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer

Novartis

Phase 1 Completed
60 enrolled
BreastCNSDermatologicEndocrineLymphoidOther hematologic neoplasmSarcomaThoracic

Astrocytoma, Brain Neoplasms, Breast Neoplasms, Burkitt Lymphoma, Carcinoma, Non-Small-Cell Lung, Craniopharyngioma, Vipoma, Ependymoma, Glioblastoma, Glucagonoma, Hodgkin Disease, Insulinoma, Adenoma, Islet Cell, Lung Neoplasms, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Medulloblastoma, Melanoma, Meningioma, Neoplasms, Oligodendroglioma, Pinealoma, Pituitary Neoplasms, Somatostatinoma, Gastrinoma, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Central Nervous System Neoplasms, Choroid Plexus Neoplasms, Neuroectodermal Tumors, Primitive, Carcinoma, Islet Cell, Glioma, Subependymal, Gliosarcoma, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Growth Hormone-Secreting Pituitary Adenoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡